(Q51029880)

English

Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: A randomized controlled trial

scientific article published on November 21, 2010

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21095214

Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: A randomized controlled trial (English)

1 reference

10.1016/J.PNPBP.2010.11.006

https://api.crossref.org/works/10.1016/J.PNPBP.2010.11.006

31 August 2024

0 references

1 reference

based on heuristic

inferred from title

author name string

Sung Joon Cho

1

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21095214

Keunyoung Yook

2

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21095214

Borah Kim

3

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21095214

Tai Kiu Choi

4

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21095214

Kang Soo Lee

5

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21095214

Yong Woo Kim

6

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21095214

Ji Eun Lee

7

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21095214

Shinyoung Suh

8

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21095214

Ki Hwan Yook

9

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21095214

Sang-Hyuk Lee

10

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21095214

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21095214

31 August 2024

publication date

21 November 2010

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21095214

full work available at URL

https://api.elsevier.com/content/article/PII:S0278584610004215?httpAccept=text/xml

1 reference

10.1016/J.PNPBP.2010.11.006

https://api.crossref.org/works/10.1016/J.PNPBP.2010.11.006

31 August 2024

https://api.elsevier.com/content/article/PII:S0278584610004215?httpAccept=text/plain

1 reference

10.1016/J.PNPBP.2010.11.006

https://api.crossref.org/works/10.1016/J.PNPBP.2010.11.006

31 August 2024

Progress in Neuro-Psychopharmacology & Biological Psychiatry

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21095214

35

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21095214

1

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21095214

208-211

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21095214

The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial

1

1 reference

10.1016/J.PNPBP.2010.11.006

https://api.crossref.org/works/10.1016/J.PNPBP.2010.11.006

31 August 2024

The diagnosis of schizophrenia

2

1 reference

10.1016/J.PNPBP.2010.11.006

https://api.crossref.org/works/10.1016/J.PNPBP.2010.11.006

31 August 2024

Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.

3

1 reference

10.1016/J.PNPBP.2010.11.006

https://api.crossref.org/works/10.1016/J.PNPBP.2010.11.006

31 August 2024

Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial

4

1 reference

10.1016/J.PNPBP.2010.11.006

https://api.crossref.org/works/10.1016/J.PNPBP.2010.11.006

31 August 2024

Add-on mirtazapine enhances effects on cognition in schizophrenic patients under stabilized treatment with clozapine

5

1 reference

10.1016/J.PNPBP.2010.11.006

https://api.crossref.org/works/10.1016/J.PNPBP.2010.11.006

31 August 2024

Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial

6

1 reference

10.1016/J.PNPBP.2010.11.006

https://api.crossref.org/works/10.1016/J.PNPBP.2010.11.006

31 August 2024

Patient assessment in clinical trials.

7

1 reference

10.1016/J.PNPBP.2010.11.006

https://api.crossref.org/works/10.1016/J.PNPBP.2010.11.006

31 August 2024

Development of a Rating Scale for Primary Depressive Illness

8

1 reference

10.1016/J.PNPBP.2010.11.006

https://api.crossref.org/works/10.1016/J.PNPBP.2010.11.006

31 August 2024

Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double-blind, randomized, placebo-controlled trial

9

1 reference

10.1016/J.PNPBP.2010.11.006

https://api.crossref.org/works/10.1016/J.PNPBP.2010.11.006

31 August 2024

The positive and negative syndrome scale (PANSS) for schizophrenia

10

1 reference

10.1016/J.PNPBP.2010.11.006

https://api.crossref.org/works/10.1016/J.PNPBP.2010.11.006

31 August 2024

Mirtazapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation

12

1 reference

10.1016/J.PNPBP.2010.11.006

https://api.crossref.org/works/10.1016/J.PNPBP.2010.11.006

31 August 2024

The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity

13

1 reference

10.1016/J.PNPBP.2010.11.006

https://api.crossref.org/works/10.1016/J.PNPBP.2010.11.006

31 August 2024

Effects of add-on mirtazapine on neurocognition in schizophrenia: a double-blind, randomized, placebo-controlled study

16

1 reference

10.1016/J.PNPBP.2010.11.006

https://api.crossref.org/works/10.1016/J.PNPBP.2010.11.006

31 August 2024

Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study

17

1 reference

10.1016/J.PNPBP.2010.11.006

https://api.crossref.org/works/10.1016/J.PNPBP.2010.11.006

31 August 2024

The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study

18

1 reference

10.1016/J.PNPBP.2010.11.006

https://api.crossref.org/works/10.1016/J.PNPBP.2010.11.006

31 August 2024

Identifiers

10.1016/J.PNPBP.2010.11.006

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21095214

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21095214

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51029880&oldid=2241013081"